Vertex Pharma Shares Slip as Co. Discontinues VX-814 Study
October 14 2020 - 5:30PM
Dow Jones News
By Stephen Nakrosis
Shares of Vertex Pharmaceuticals Inc. are trading lower in
Wednesday's after-hours session, following news the company is
discontinuing a Phase 2 study of its VX-814 in patients with
alpha-1 antitrypsin deficiency.
"Based on the safety and pharmacokinetic profile of VX-814
observed to date in a Phase 2 trial in AATD, Vertex has decided to
stop dosing in the trial and will discontinue development of
VX-814," the company said.
Alpha-1 antitrypsin deficiency is a genetic disorder that can
cause lung or liver disease.
At 4:51 p.m. EDT, the company's shares were trading 9.2% lower
at $246.12 per share. Volume at the time topped 115,000 shares.
The stock finished the day's regular-trading session with a 1.7%
loss, closing at $271.46.
Year to date, the stock is up over 23%.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
October 14, 2020 17:15 ET (21:15 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Apr 2023 to Apr 2024
